

Salivary Gland Neoplasms: Navigating Difficult Surgical Landscapes


Raisa Tikhtman, MD

Assistant Professor

Head and Neck Surgical Oncology and Microvascular Reconstruction

22nd Annual Aultman Cancer Symposium

Saturday, September 27, 2025



Learning Objectives


- Describe key features of the most common neoplasms arising in the major and minor salivary glands including clinical history and histology.
- Review the role of surgery in curative approaches to salivary gland malignancy.
- Discuss approaches to facial nerve preservation in difficult cases.

Outline

1. Epidemiology
2. Clinical features
3. Anatomic overview
4. Treatment paradigms
5. Surgical approaches
6. Case presentations

Epidemiology

- Salivary gland malignancy is overall quite rare
 - 6-8% of head and neck cancers
 - Incidence of 1.1 cases per 100,000 individuals in United States
- Greater predominance in women <50 years; >50 years more common in men
- Salivary gland neoplasms in children much more likely malignant (50%)
 - Incidence 0.8-1.4 per 1,000,000 children



Boukheris et al, 2009

Epidemiology


- Majority of salivary gland neoplasms are benign (80%)
 - Pleomorphic adenoma by far most common
 - Warthin's tumors (smoking predilection)
- Parotid is most common tumor subsite
- The smaller the gland, the more likely the tumor is malignant**

		Parotid gland		Submandibular gland		Minor salivary glands	
Pleomorphic adenoma	BENIGN	70%	80%	50%	60%	15%	20%
Warthin's tumor		5%					
Adenoid cystic carcinoma	MALIGNANT	5%	20%	20%	40%	75%	80%
Mucoepidermoid carcinoma		10%		15%			


Gaillard et al, 2015

Histologic subtypes


Mucoepidermoid carcinoma




Adenoid cystic carcinoma



Squamous cell carcinoma




Acinic cell carcinoma




Clinical presentation

- Most commonly present with neck mass
- Red flag features for malignancy:
 - Rapid growth
 - Local or referred pain
 - Facial paresis
 - Fixation of overlying skin
 - Trismus
- 14-20% with clinical nodal metastases





Clinical presentation

- **Facial nerve paralysis in the presence of a parotid mass = malignancy** until proven otherwise
 - Indicative of perineural invasion
 - Less commonly mass effect
 - Low likelihood of recovering native nerve function with treatment




Anatomy – Parotid gland




-  **Parotid gland and duct**
-  **Zygomatic arch** (superior border)
-  **Sternocleidomastoid** (posterior border)
-  **Masseter** (anterior border)
-  **Buccinator**

Anatomy – Parotid gland




Anatomy – Parotid gland




Rai et al, 2024

Pre-styloid parapharyngeal space mass




Vargas et al, 2022

Anatomy – Submandibular gland




<https://teachmeanatomy.info/head/organs/salivary-glands/submandibular/>

Anatomy – Submandibular gland



<https://anatomyqa.com/submandibular-gland/>

Anatomy – Minor salivary glands



Tumor staging – AJCC 8th ed.

Major salivary gland

Primary Tumor (T)

TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma <i>in situ</i>
T1	Tumor 2 cm or smaller in greatest dimension without extraparenchymal extension*
T2	Tumor larger than 2 cm but not larger than 4 cm in greatest dimension without extraparenchymal extension*
T3	Tumor larger than 4 cm and/or tumor having extraparenchymal extension*
T4	Moderately advanced or very advanced disease
T4a	Moderately advanced disease Tumor invades skin, mandible, ear canal, and/or facial nerve
T4b	Very advanced disease Tumor invades skull base and/or pterygoid plates and/or encases carotid artery

Note: Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.

Minor salivary gland


Site specific – ie. oral cavity (DOI), oropharynx

Treatment

- Resectable disease:
 - Primary surgical resection followed by pathology-guided adjuvant therapies is the standard of care for salivary gland malignancies
 - Goal: free surgical margins
 - Proximity to facial nerve limits extent of margins
 - Excellent disease control for T1-T2N0 low- and intermediate-grade mucoepidermoid and acinic cell carcinoma with surgery alone (Zenga et al, 2018; Zenga et al, 2019)

Treatment

- Indications for neck dissection:
 - Clinical positive nodal disease
 - Advanced-stage tumors (T3 and T4)
 - High-grade malignancies (>20% occult nodal disease):
 - High-grade mucoepidermoid carcinoma
 - Salivary ductal carcinoma
 - Carcinoma ex-pleomorphic adenoma



Treatment

- Postsurgical adjuvant therapies
 - Radiation
 - All patients with adenoid cystic carcinoma (including early-stage)
 - Improves locoregional control but not distant metastatic risk
 - High-grade histology
 - Positive margins
 - Perineural invasion
 - Lymphovascular invasion
 - T3-4 tumors
 - N+ disease

Treatment

- Postsurgical adjuvant therapies
 - Chemotherapy
 - Not typically recommended outside of clinical trial
 - No RCTs comparing adjuvant RT vs CRT for salivary gland malignancy

Treatment


- Unresectable disease/comorbidities precluding surgery
 - Consider definitive radiation (70 Gy)
 - Unclear additional benefit of chemotherapy
- Metastatic disease
 - Molecular testing to assess for targeted therapy candidacy
 - Androgen receptor (AR) and HER2-neu testing
 - Clinical trials

Surgical approaches

- Major salivary gland
 - Parotidectomy
 - Transcervical




Modified Blair incision



Surgical approaches

- Major salivary gland
 - Parotidectomy
 - Transcervical
 - Mandibulotomy combined approach
 - Endoscopic



<https://arrangoizmd.com/2020/04/07/paramedian-madibulotomy/>

Surgical approaches

- Minor salivary gland
 - Transoral
 - Transcervical
 - Robotic



<https://surgeryreference.aofoundation.org/cmfr/reconstruction/midface/midface-brown-i-palate/obturators>




<https://www.entcentral.co.nz/robotic-head-and-neck/>

Surgical approaches

- Indications for regional pedicled flaps or free tissue transfer
 - Significant soft tissue or bony defect following surgery
 - Functional and/or cosmetic restoration




Ferrari et al, 2019



Juturu et al, 2023

Management of the facial nerve

- Often center of intraoperative decision making
- If facial nerve is functional preoperatively:
 - Attempt preservation if tumor can be dissected off
 - Nerve resection if tumor is visibly encasing or grossly infiltrating branches



<https://www.jaypeedigital.com/book/9788180618475/chapter/ch4>

Management of the facial nerve



- If there is facial paralysis preoperatively:
 - Typically requires nerve resection (major branches vs main trunk)
 - Can consider preserving functional branches of nerve
 - Consideration of combined facial reanimation procedure(s)
- In general, resection of facial nerve branches indicated only to facilitate complete margin clearance or when nerve is grossly infiltrated/encased by tumor

Case presentation 1

- 68 yo M with right parotid mass initially treated for acute parotitis, refractory to antibiotics
 - Continued progression of mass and increasing pain
 - Erupted through skin
 - Biopsy: **high-grade mucoepidermoid carcinoma**
 - Exam:
 - Firm, immobile parotid mass with erosion through skin
 - Incomplete right facial paralysis with mild lagophthalmos, blunted nasolabial fold




Case presentation 1



Case presentation 1

cT4aN0M0



Case presentation 1

- Surgical resection and reconstruction:
 - Radical parotidectomy with resection on 7 cm x 6 cm overlying skin, right levels 2-4 selective neck dissection, right anterolateral thigh free flap reconstruction, static sling, facial nerve cable grafting
 - Resection through masseter muscle
 - Sacrifice of encased upper facial nerve branches with preservation of marginal mandibular nerve
 - Frozen section from proximal end of upper division negative for carcinoma
 - Circumferential skin frozen margins negative for carcinoma
 - Right tensor facia lata sling to oral commissure for static facial reanimation
 - Use of nerve to vastus lateralis for cable grafting of right buccal branch

Case presentation 1

- Surgical pathology:
 - 5.2 cm high-grade mucoepidermoid carcinoma with extension through masseter and overlying skin, +PNI/LVI
 - All skin margins negative for carcinoma
 - 1/28 involved lymph nodes without ENE
 - Final staging: **pT4aN1M0**
- Tumor board recommendation:
 - Referred for **adjuvant radiation**

Case presentation 1




Case presentation 2



- 56 yo F with a history of low-grade acinic cell carcinoma of the left parotid s/p prior superficial parotidectomy in 2022 with 3.8 cm tumor with dermal invasion and positive margins; -PNI/LVI, no adjuvant therapies.
 - New left retroauricular mass without association pain
 - Biopsy: **low-grade acinic cell carcinoma**
 - Solid Tumor NGS panel: no identifiable molecular alterations
 - Exam:
 - Firm left postauricular mass overlying anterior mastoid tip
 - Residual marginal mandibular nerve paresis



Case presentation 2



Case presentation 2



Case presentation 2

- Surgical resection and reconstruction:
 - Head and Neck Surgical Oncology:
 - Left subtotal salvage parotidectomy with preservation of facial nerve, left selective neck dissection (levels 1-3), partial auriclectomy, radical resection of postauricular skin, left radial forearm free flap, FTSG
 - Neurosurgery:
 - Left retrolabyrinthine resection, mesh cranioplasty

Case presentation 2

- Surgical pathology:
 - 3.5 cm low-grade acinic cell carcinoma with multifocal dermal invasion; +PNI, - LVI
 - Negative soft tissue margin except with tumor left over transverse dural venous sinus
 - 1/67 lymph nodes positive with ENE
 - Final staging: **pT4bN2M0**
- Tumor board recommendation: **adjuvant RT**

Case presentation 2



POD 4

Case presentation 2

- Post-treatment course:
 - PET CT with new lytic lesions in right iliac bone, FDG avid
 - **SBRT for presumed metastatic disease**

Conclusions

- Salivary malignancies demonstrate vast heterogeneity clinically and prognostically
- Typically require multidisciplinary care with lifelong surveillance particularly for high-grade disease
- Approach to facial nerve dependent on preoperative functionality and intraoperative findings with potential for restorative procedures

Comments?



THANK YOU!

References

- Steuer CE, Hanna GJ, Viswanathan K, et al. The evolving landscape of salivary gland tumors. *CA Cancer J Clin*. 2023;73(6):597-619. doi:10.3322/caac.21807
- Boukheris H, Curtis RE, Land CE, Dores GM. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. *Cancer Epidemiol Biomarkers Prev*. 2009;18(11):2899-2906. doi:10.1158/1055-9965.EPI-09-0638
- Pohar S, Gay H, Rosenbaum P, et al. Malignant parotid tumors: presentation, clinical/pathologic prognostic factors, and treatment outcomes. *Int J Radiat Oncol Biol Phys*. 2005;61(1):112-118. doi:10.1016/j.ijrobp.2004.04.052
- Wine H, Baum M. Jacques-Louis David's tumour: an opportunity to study the natural history of a pleomorphic adenoma of the parotid gland. *J R Soc Med*. 2008;101(12):583-586. doi:10.1258/jrsm.2008.080221
- Stennert E, Kisner D, Jungehuelsing M, et al. High Incidence of Lymph Node Metastasis in Major Salivary Gland Cancer. *Arch Otolaryngol Head Neck Surg*. 2003;129(7):720–723. doi:10.1001/archotol.129.7.720
- Vargas N, Assadsangabi R, Birkeland A, et al. Pre-styloid parapharyngeal space masses—Tumor margins as a predictor of benign versus malignant histology on pre-operative CT or MRI. *The Neuroradiology Journal*. 2022;35(6):701-705. doi:[10.1177/19714009221089027](https://doi.org/10.1177/19714009221089027)
- Rai P, Bhattacharya K, Rastogi S, et al. Beyond the throat: Imaging of parapharyngeal space lesions. *Clin Radiol*. 2024;79(12):912-920. doi:10.1016/j.crad.2024.08.030
- Zenga J, Parikh AS, Emerick KS, et al: Close margins and adjuvant radiotherapy in acinic cell carcinoma of the parotid gland. *JAMA Otolaryngol Head Neck Surg* 144:1011-1016, 2018
- Zenga J, Yu Z, Parikh A, et al: Mucoepidermoid carcinoma of the parotid: Very close margins and adjuvant radiotherapy. *ORL J Otorhinolaryngol Relat Spec* 81:55-62, 2019
- Stodulski D, Mikaszewski B, Majewska H, et al: Close surgical margin after conservative parotidectomy in early stage low-/intermediate-grade parotid carcinoma: Outcome of watch and wait policy. *Oral Oncol* 68:1-4, 2017
- Geiger JL, Ismaila N, Beadle B, et al. Management of Salivary Gland Malignancy: ASCO Guideline. *J Clin Oncol*. 2021;39(17):1909-1941. doi:10.1200/JCO.21.00449
- Cheraghlou S, Kuo P, Mehra S, et al. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. *Head Neck*. 2018;40(7):1343-1355. doi:10.1002/hed.24984
- Ferrari, S., Ferri, A., Bianchi, B., Sesenna, E. (2019). Principles of Reconstruction: Reconstruction of the Parotid Area. In: Licitra, L., Locati, L. (eds) *Salivary Gland Cancer*. Springer, Cham. https://doi.org/10.1007/978-3-030-02958-6_9
- Juturu, U., Shah, A., Reddeppa, S.K. et al. A Palatal Approach of Bipaddled Radial Forearm Free Flap for the Reconstruction of Oral Submucous Fibrosis. *J. Maxillofac. Oral Surg*. **22** (Suppl 1), 176–178 (2023). <https://doi.org/10.1007/s12663-023-01898-4>

